重组表达S100A9蛋白枯草芽孢杆菌对哮喘小鼠的干预作用OA

To investigate the therapeutic effect of S100A9 recombinant Bacillus subtilis on asthma,the effects and optimal dosage of S100A9 recombinant Bacillus subtilis was explored using the OVA-induced asthmatic mouse from the molecular expression and pathological levels.Compared with the groups of asthma and vector control,the low-dose recombinant bacteria group(1.02×107 CFU/mL)showed a significant reduction in actions of wheezing and arching back,an increase in body weight,and a reduction in lung coefficients;compared with the low-dose,the effects were weaker in the medium-dose-treated group(1.18×108 CFU/mL)and the high-dose-treated group(1.25×109 CFU/mL);pathological sections showed a significant reduction of inflammatory cells infiltration in the airways,and a reduction of thickness of the bronchial tubes(P<0.05);and the expressions of IL-5,IL-6,and IL-13 were significantly decreased in the lung tissues;the mRNA levels of Muc5ac and Muc5b were also significantly reduced(P<0.05);the levels of IL-6 and TNF-α in the serum of mice in the low-dose recombinant bacteria-treated group was significantly reduced;the content of SOD and CAT enzymes in the lung tissues were increased,and there was a significant recovery of the MDA indexes;the number of eosinophils in the alveolar lavage fluid was significantly reduced(P<0.05).The above results indicated that low-dose S100A9 recombinant Bacillus subtilis had a better treating effects on asthma.